SCHEDULE: Enzon, Viskase Merger Terms Amended; Icahn Backs Deal

Enzon Pharmaceuticals and Viskase amend their merger agreement, adjusting ownership stakes, extending the deadline, and securing continued support from Icahn Enterprises.

Summary

• Amendment No. 17 to Schedule 13D details changes to the merger agreement between Enzon Pharmaceuticals, Inc. and Viskase.
• Viskase stockholders will now own 55% of the combined company post-merger, an adjustment from previous terms.
• The exchange ratio for Enzon's Series C Preferred Stock will be based on the 20-day volume weighted average price (VWAP) of Enzon shares prior to the amendment.
• Enzon's minimum cash requirement at closing has been reduced.
• Enzon will effect a 1-for-100 reverse stock split before the merger's effective time.
• The merger termination date has been extended from December 31, 2025, to March 31, 2026.
• Enzon and Merger Sub waived certain known inaccuracies, breaches, or non-compliance by Viskase prior to the amendment date.
• The definition of "Viskase Material Adverse Effect" was modified to exclude effects from facts known prior to the amendment date.
• Icahn Enterprises Holdings and affiliates reaffirmed support, agreeing to approve the merger and exchange their Series C Preferred Stock into common shares based on liquidation preference and the 20-Day VWAP.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While a reverse stock split and waiver of known breaches introduce some caution, the extension of the merger deadline and continued strong support from a major shareholder like Icahn Enterprises indicate progress towards deal completion, which is generally favorable for a company in a merger process.

Positives

• Extension of the merger termination date to March 31, 2026, provides more time for deal completion.
• Continued strong support from Icahn Enterprises Holdings and affiliates for the merger and related corporate actions.
• Reduction in Enzon's minimum cash requirement at closing may ease financial constraints for the transaction.

Negatives

• Enzon will effect a 1-for-100 reverse stock split, which can sometimes be perceived negatively by the market.
• Enzon and Merger Sub waived known inaccuracies or breaches by Viskase, potentially exposing the combined entity to undisclosed issues.
• Modification of the "Viskase Material Adverse Effect" definition limits recourse for issues known prior to the amendment date.

Risks

• The merger may still not be consummated despite the extended deadline.
• The reverse stock split could negatively impact share liquidity or investor perception.
• Waiver of known Viskase breaches could lead to unforeseen liabilities or operational challenges for the combined company.
• The adjusted ownership structure and exchange ratios may not be favorable to all existing shareholders.

Future Outlook

The parties anticipate the consummation of the merger between Enzon Pharmaceuticals and Viskase, with an extended deadline of March 31, 2026. Prior to the merger, Enzon will execute a 1-for-100 reverse stock split.

Industry Context

This filing primarily concerns specific corporate actions related to a merger between two companies, Enzon Pharmaceuticals and Viskase. It does not provide broader insights into industry trends or competitive landscape beyond the immediate transaction.

Corporate Governance

Related Party Transactions

• Icahn Enterprises Holdings L.P. and its affiliates, as significant beneficial owners (48.6%), entered into an amendment to the IEH Support Agreement with the Issuer and Viskase, agreeing to specific actions to facilitate the merger.
• Icahn Enterprises Holdings and affiliates will exchange their Series C Preferred Stock into common shares based on the 20-Day VWAP and full liquidation preference.

Stakeholder Impact

• Shareholders (Enzon): Will experience a 1-for-100 reverse stock split, potentially impacting share price and liquidity. Their ownership percentage in the combined entity will be affected by the Viskase stockholders owning 55%.
• Viskase Stockholders: Will own 55% of the combined company, indicating a significant stake in the merged entity.
• Series C Preferred Stockholders (Enzon, specifically Icahn): Their preferred shares will be exchanged for common shares based on a 20-Day VWAP and full liquidation preference, converting their investment into common equity.
• Creditors: The reduction in Enzon's minimum cash requirement at closing could indirectly affect the company's immediate liquidity position, though the overall merger is intended to create a stronger entity.

Next Steps

• Enzon Pharmaceuticals to effect a 1-for-100 reverse stock split.
• Icahn Enterprises Holdings and affiliates to deliver written consents approving the merger and certificate of incorporation amendment.
• Icahn Enterprises Holdings and affiliates to exchange Series C Preferred Stock into common shares.
• Consummation of the merger between Enzon Pharmaceuticals and Viskase by March 31, 2026.

Key Dates

Keywords

Enzon Pharmaceuticals, Viskase, Merger Agreement, Icahn Enterprises, Schedule 13D, Reverse Stock Split, Corporate Governance, Shareholder Support